Myoxant50 mg

Myoxant is a centrally-acting skeletal muscle relaxant used to relieve painful muscle spasm and spasticity. Its use is classified below by strength of supporting evidence.

Established / Well-Supported Use

• Spasticity following stroke in adults – the indication with the strongest regulatory and clinical evidence for oral Myoxant.

Guideline-Supported / Regionally Established Uses

• Painful reflex muscle spasm associated with disorders of the spine (e.g., cervical and lumbar spondylosis, low back pain).
• Spasticity associated with other neurological disorders, such as multiple sclerosis, myelopathy, or encephalomyelitis.

These uses are widely prescribed in South Asia, including Bangladesh, reflecting long-standing regional clinical practice. However, regulators in some regions (e.g., the European Medicines Agency) concluded that evidence for indications outside post-stroke spasticity is comparatively weaker, so Myoxant should be used for the shortest effective duration and only when a physician judges it clinically appropriate.

Adjunct Use

• Myoxant is often used as an adjunct to physiotherapy, rest, and analgesics/NSAIDs rather than as a standalone treatment for musculoskeletal pain.

Only a qualified physician should decide whether Myoxant is appropriate for a given patient.

Each tablet of Tolperisone Hydrochloride generally contains Tolperisone Hydrochloride as the active ingredient, commonly available in strengths of 50 mg and 150 mg for oral use. Exact strength, excipients, and available dosage forms vary by manufacturer; refer to the product label of the specific formulation dispensed.

Myoxant is a centrally-acting muscle relaxant, chemically related to local anaesthetics such as lidocaine, used to treat painful, disabling muscle spasm and increased muscle tone (spasticity). Unlike some other centrally-acting muscle relaxants, Myoxant is notable for producing comparatively less sedation at therapeutic doses, a distinguishing feature often cited in the literature, although individual response varies and some patients may still experience drowsiness.

Myoxant is available as oral tablets and is used under medical supervision as part of a broader treatment plan that may include physiotherapy and analgesics.

Myoxant belongs to the therapeutic class of centrally-acting skeletal muscle relaxants (myotonolytics).

Pharmacodynamics

Tolperisone Hydrochloride acts primarily in the central nervous system, at the level of the brainstem reticular formation and spinal cord. It has a membrane-stabilizing action, chemically related to local anaesthetics such as lidocaine, and is thought to reduce pathologically increased muscle tone by blocking voltage-gated sodium and calcium channels, which dampens the excessive firing of mono- and polysynaptic spinal reflexes responsible for spasm and spasticity, without significantly depressing normal voluntary motor function.

Pharmacokinetics

After oral administration, Tolperisone Hydrochloride is absorbed relatively rapidly, with peak plasma concentration reached within roughly 0.5–1.5 hours. It undergoes extensive first-pass hepatic metabolism, and its metabolites are eliminated mainly via the kidneys. Because of this, dose adjustment is required in patients with significant renal or hepatic impairment (see Use in Special Populations).

Myoxant tablets are usually taken orally, after meals, swallowed whole with a glass of water without crushing or chewing (unless the product label states otherwise). Doses should be spaced evenly through the day as directed by the physician. If a dose is missed, take it as soon as remembered unless it is close to the time of the next dose, in which case skip the missed dose — do not double the next dose.

Myoxant has a relatively low potential for clinically significant drug interactions compared with some other central muscle relaxants, but the following should be noted:

• CNS depressants (e.g., benzodiazepines, sedatives, opioids, alcohol): concurrent use may increase sedation or muscle-relaxant effect; combine cautiously and only under medical supervision.
• Other muscle relaxants: additive muscle-relaxant/hypotonic effects are possible; dose adjustment may be needed.
• Antihypertensive or blood-pressure-lowering agents: caution advised due to a potential additive hypotensive effect reported with Myoxant.

Always inform the physician about all medicines, supplements, and herbal products being used before starting Myoxant.

Most people tolerate Myoxant well, but side effects can occur.

Patients should seek immediate medical attention if signs of a serious allergic reaction occur while taking Myoxant.

Pregnancy: Data on the use of Myoxant in pregnant women are limited/insufficient. As a precaution, Myoxant should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether Myoxant or its metabolites pass into human breast milk. Because safety data are insufficient, a decision on whether to continue breastfeeding or the medicine should be made with a physician, taking into account the benefit of the medicine to the mother.

Hypersensitivity/anaphylaxis signal: Regulatory safety reviews, including by the European Medicines Agency, have specifically noted that a notable proportion of reported adverse reactions with Myoxant are hypersensitivity reactions, some serious (including anaphylaxis), occurring even in patients with no prior history of allergy and sometimes after the first dose. Patients taking Myoxant should be counselled to stop the medicine and seek urgent medical care if they develop rash, itching, swelling, wheezing, breathing difficulty, or fainting.

Driving and operating machinery: Although Myoxant is associated with comparatively less sedation than some other centrally-acting muscle relaxants, individual response varies and some patients may experience dizziness or drowsiness; caution is advised before driving or operating machinery until the individual response to Myoxant is known.

Renal/hepatic impairment: Use with caution and reduced/adjusted dosing in patients with significant renal or hepatic impairment (see Dosage and Administration).

Duration of use: Long-term safety data for extended use of Myoxant are limited; treatment should generally be for the shortest period needed, with periodic medical review if prolonged use is required (see Duration of Treatment).

Reported symptoms of Myoxant overdose may include muscle weakness, low blood pressure, drowsiness, nausea/vomiting, and in severe cases, respiratory difficulty or seizures; rare fatalities have been reported in intentional overdose. There is no specific antidote. If overdose of Myoxant is suspected, seek immediate medical attention or contact emergency services/poison control; treatment is supportive and symptomatic under medical supervision. Do not attempt to manage a suspected overdose at home.

Store Myoxant at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric

Safety and efficacy of Myoxant in children are not well established in most regulatory labeling; use in children should only occur under direct pediatric medical supervision where locally indicated (see Pediatric Uses).

Elderly

No specific dose adjustment is generally required based on age alone, but elderly patients may be more sensitive to blood-pressure-lowering or sedative effects; start at the lower end of the dose range and monitor closely.

Renal Impairment

Use with caution; dose reduction may be needed (see Dosage and Administration).

Hepatic Impairment

Use with caution; dose reduction may be needed given hepatic metabolism of Myoxant.

Pregnancy and Lactation

See the Pregnancy and Lactation section.

Because long-term safety data for Myoxant are limited, it is generally used for short to medium-term relief of acute painful muscle spasm, typically for a few days to a few weeks alongside physiotherapy and other measures. If symptoms persist or treatment is needed beyond a few weeks, the prescribing physician should periodically reassess the ongoing need for Myoxant.

Centrally-acting skeletal muscle relaxant (myotonolytic agent).

Tolperisone Hydrochloride acts centrally on the reticular formation of the brainstem and spinal cord, exerting a membrane-stabilizing effect related to local anaesthetics. It blocks voltage-gated sodium and calcium channels on nerve membranes, reducing pathologically increased excitability of mono- and polysynaptic reflex pathways that drive muscle spasm and spasticity, thereby lowering excessive muscle tone without markedly impairing normal voluntary muscle strength.

The safety and efficacy of Myoxant in children have not been firmly established in most regulatory reviews, and current European labeling limits oral Myoxant-containing medicines to adult use for post-stroke spasticity. In some regions, Myoxant has historically been used in children with weight-based dosing under specialist supervision for spasticity of neurological origin, but this is not universally supported by robust pediatric trial data. Myoxant should not be given to a child except on the specific advice and supervision of a pediatrician, who will weigh the potential benefit against the limited safety data available in this age group.